Nanostrategies in the war against multidrug resistance in leukemia

Nanostrategies in the war against multidrug resistance in

leukemia

Review Article 

AUTHORS: Alphy Rose-James¹, TT Sreelekha¹, Suraj K. George^2*

AFFILIATIONS: ¹Laboratory of Biopharmaceuticals, Division of Cancer Research, Regional Cancer Centre, Thiruvananthapuram-695 011, Kerala, India. ²Dept. of Hematopathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA

 

* CORRESPONDING AUTHOR: Dr. Suraj Konnath George PhD. Dept. of Hematopathology. Division of Pathology and Laboratory Medicine. University of Texas MD Anderson Cancer Center. 1515 Holcombe Blvd, Houston, TX 77030, USA. Ph: 001-7137927692   Fax: 001-7137927273. Email: skonnath@mdanderson.org or surajrcc@gmail.com

 Abstract

Chemotherapy is the cornerstone of treatment for haematological malignancies. Despite innovative advances in the understanding of this complex disease, multidrug resistance (MDR) is still a major culprit for the treatment failure, especially in leukemia. Conventional combinatorial therapy is a major decoy to circumvent MDR, but those are frequently thwarted by the evolving intricacies of the cancer paradigm. The advent of nanomedicine has ushered a new era with striking pharmacokinetic drug properties far enough to combat MDR. Physicochemical elements such as co-encapsulation, drug influx, ratiometric drug loading, temporal sequencing on drug release, and selective targeting moiety have been better tailored within the nanotherapeutics to overcome MDR. This review focuses on a plethora of nanostrategies and nanoplatforms which have been developed so far to battle MDR in leukemia.

Download full text (PDF) from OncoDrugs